Difference between revisions of "LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5 (Q9853)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Published In Name String (P102): Invest. N. Drugs, #quickstatements; #temporary_batch_1590006349955)
(‎Created claim: Page(s) (P105): 169-176, #quickstatements; #temporary_batch_1590074839150)
 
(2 intermediate revisions by the same user not shown)
Property / Volume
 +
33
Property / Volume: 33 / rank
 +
Normal rank
Property / title
 +
A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English)
Property / title: A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English) / rank
 +
Normal rank
Property / Page(s)
 +
169-176
Property / Page(s): 169-176 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    LoConte NK
    0 references
    2015
    0 references
    Invest. N. Drugs
    0 references
    33
    0 references
    A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English)
    0 references
    169-176
    0 references